9966 — Alphamab Oncology Balance Sheet
0.000.00%
Last trade - 00:00- HK$9.71bn
- HK$8.30bn
- CNY566.24m
Annual balance sheet for Alphamab Oncology, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,985 | 1,350 | 1,407 | 1,571 | 1,350 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 67.5 | 79.5 | 72.5 | 58.1 | 136 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,117 | 1,495 | 1,559 | 1,711 | 1,594 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 545 | 621 | 578 | 529 | 497 |
| Long Term Notes Receivable | |||||
| Total Assets | 2,705 | 2,118 | 2,137 | 2,242 | 2,097 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 637 | 385 | 267 | 254 | 281 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 835 | 560 | 465 | 410 | 386 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,870 | 1,558 | 1,672 | 1,832 | 1,711 |
| Total Liabilities & Shareholders' Equity | 2,705 | 2,118 | 2,137 | 2,242 | 2,097 |
| Total Common Shares Outstanding |